Have a feature idea you'd love to see implemented?
Let us know!
CTXR Citius Pharmaceuticals Inc
Price (delayed)
$0.1651
Market cap
$29.84M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.24
Enterprise value
$12.21M
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.
Highlights
CTXR's debt is down by 40% YoY and by 15% QoQ
Citius Pharmaceuticals's quick ratio has increased by 43% QoQ but it has decreased by 25% YoY
Citius Pharmaceuticals's equity has decreased by 12% YoY but it has increased by 8% QoQ
The net income is down by 25% year-on-year and by 6% since the previous quarter
The EPS has declined by 20% year-on-year
Key stats
What are the main financial stats of CTXR
Market
Valuations
Earnings
Shares outstanding
180.73M
Market cap
$29.84M
Enterprise value
$12.21M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.35
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$37.72M
EBITDA
-$37.51M
Free cash flow
-$29.09M
Per share
Balance sheet
Liquidity
EPS
-$0.24
Free cash flow per share
-$0.17
Book value per share
$0.47
Revenue per share
$0
TBVPS
$0.5
Total assets
$97.09M
Total liabilities
$10.81M
Debt
$320,011
Equity
$85.68M
Working capital
$23.85M
Debt to equity
0
Current ratio
6.75
Quick ratio
4.32
Net debt/EBITDA
0.47
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-40.9%
Return on equity
-46.7%
Return on invested capital
-59%
Return on capital employed
-40.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTXR stock price
How has the Citius Pharmaceuticals stock price performed over time
Intraday
-2.83%
1 week
-49.73%
1 month
-57.03%
1 year
-78.61%
YTD
-78.18%
QTD
-67.02%
Financial performance
How have Citius Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$41.07M
Net income
-$38.29M
Gross margin
N/A
Net margin
N/A
The net income is down by 25% year-on-year and by 6% since the previous quarter
The operating income fell by 20% YoY and by 5% QoQ
Growth
What is Citius Pharmaceuticals's growth rate over time
Valuation
What is Citius Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.35
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 20% year-on-year
The price to book (P/B) is 79% lower than the 5-year quarterly average of 1.7 and 75% lower than the last 4 quarters average of 1.4
Citius Pharmaceuticals's equity has decreased by 12% YoY but it has increased by 8% QoQ
Efficiency
How efficient is Citius Pharmaceuticals business performance
CTXR's ROE is down by 50% YoY and by 10% from the previous quarter
The company's return on assets fell by 47% YoY and by 10% QoQ
The ROIC has contracted by 21% YoY and by 4.4% from the previous quarter
Dividends
What is CTXR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTXR.
Financial health
How did Citius Pharmaceuticals financials performed over time
Citius Pharmaceuticals's quick ratio has increased by 43% QoQ but it has decreased by 25% YoY
Citius Pharmaceuticals's current ratio has increased by 31% QoQ but it has decreased by 4.9% YoY
CTXR's debt is 100% lower than its equity
The debt to equity has plunged by 100% YoY
CTXR's debt is down by 40% YoY and by 15% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.